脾多肽联合化疗治疗乳腺癌的临床疗效观察

Clinical efficacy of lienal polypeptide in adjuvant chemotherapy of breast cancer

摘要:

摘要：目的  探讨乳腺癌术后辅助化疗患者应用脾多肽的临床效果。方法  53例术后行辅助化疗的乳腺癌患者随机分为观察组（27例）和对照组（26例），观察组化疗同时加用脾多肽，对照组仅给予辅助化疗。对比两组患者化疗后的毒副反应，分析外周血T淋巴细胞亚群比例,并利用卡氏（KPS）评分评估生活质量。结果  化疗后观察组重度低白细胞血症、贫血、低血小板血症发生率均低于对照组。观察组CD3+、CD4+ T淋巴细胞及CD4/CD8比值均高于对照组，CD8+ T淋巴细胞低于对照组。根据KPS评分，观察组的生活质量优于对照组。结论  乳腺癌术后辅助化疗过程中应用脾多肽能有效减轻骨髓抑制，增强免疫应答，提高生活质量。

Abstract:

Abstract: Objective To evaluate the clinical effects of lienal polypeptide in postoperative adjuvant chemotherapy of breast cancer. Methods Fifty-three breast cancer patients intended to have adjuvant chemotherapy were randomly divided into observation group (27 cases) and control group (26 cases). The patients in the observation group were treated with chemotherapy and lienal polypeptide, whereas those in the control group only received chemotherapy. Then adverse reactions, proportions of T lymphocyte subsets in peripheral blood, and KPS for life quality were analyzed and compared between the two groups. Results The incidences of severe granulocytopenia, anemia and thrombopenia in the observation group were significantly lower than those in control group. The proportions of CD3+, CD4+ T lymphocytes and CD4/CD8 ratio were higher in the observation group, while CD8+ T lymphocytes were fewer in the observation group in comparison to the control group. According to the average KPS score, the patients in the observation group had better quality of life than those in the control group. Conclusions Application of lienal polypeptide during postoperative adjuvant chemotherapy for breast cancer can effectively reduce myelosuppression, enhance immunologic response and increase life quality.